sample_name,protocol,organism,read_type,data_source,srr,srx,sample_title,sample_geo_accession,sample_status,sample_submission_date,sample_last_update_date,sample_type,sample_channel_count,sample_source_name_ch1,sample_organism_ch1,sample_taxid_ch1,sample_treatment_protocol_ch1,sample_growth_protocol_ch1,sample_molecule_ch1,sample_label_ch1,sample_source_name_ch2,sample_organism_ch2,sample_taxid_ch2,sample_treatment_protocol_ch2,sample_growth_protocol_ch2,sample_molecule_ch2,sample_label_ch2,sample_description,sample_platform_id,sample_contact_name,sample_contact_institute,sample_contact_address,sample_contact_city,sample_contact_zip_postal_code,sample_contact_country,sample_supplementary_file,sample_series_id,sample_data_row_count,id_ref,value,big_key,sample_id,tissue
pca_a5_n,,,,,,,PCa_A5_N,GSM1471696,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471696/suppl/GSM1471696_US22502614_252800412689_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471696,A5,Prostate adenocarcinoma
pca_a5_ds,,,,,,,PCa_A5_DS,GSM1471697,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471697/suppl/GSM1471697_US22502614_252800412689_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471697,A5,Prostate adenocarcinoma
pca_aa90_n,,,,,,,PCa_AA90_N,GSM1471698,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471698/suppl/GSM1471698_US22502614_252800412689_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471698,AA90,Prostate adenocarcinoma
pca_aa90_ds,,,,,,,PCa_AA90_DS,GSM1471699,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471699/suppl/GSM1471699_US22502614_252800412689_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471699,AA90,Prostate adenocarcinoma
pca_b11_n,,,,,,,PCa_B11_N,GSM1471700,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471700/suppl/GSM1471700_US22502614_252800412689_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471700,B11,Prostate adenocarcinoma
pca_b11_ds,,,,,,,PCa_B11_DS,GSM1471701,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471701/suppl/GSM1471701_US22502614_252800412689_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471701,B11,Prostate adenocarcinoma
pca_aa97_n,,,,,,,PCa_AA97_N,GSM1471702,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471702/suppl/GSM1471702_US22502614_252800412689_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471702,AA97,Prostate adenocarcinoma
pca_aa97_ds,,,,,,,PCa_AA97_DS,GSM1471703,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471703/suppl/GSM1471703_US22502614_252800412689_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471703,AA97,Prostate adenocarcinoma
pca_y50_n,,,,,,,PCa_Y50_N,GSM1471704,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471704/suppl/GSM1471704_US22502614_252800412690_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471704,Y50,Prostate adenocarcinoma
pca_y50_ds,,,,,,,PCa_Y50_DS,GSM1471705,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471705/suppl/GSM1471705_US22502614_252800412690_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471705,Y50,Prostate adenocarcinoma
pca_y44_n,,,,,,,PCa_Y44_N,GSM1471706,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471706/suppl/GSM1471706_US22502614_252800412690_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471706,Y44,Prostate adenocarcinoma
pca_y44_ds,,,,,,,PCa_Y44_DS,GSM1471707,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471707/suppl/GSM1471707_US22502614_252800412690_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471707,Y44,Prostate adenocarcinoma
pca_p55_n,,,,,,,PCa_P55_N,GSM1471708,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471708/suppl/GSM1471708_US22502614_252800412690_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471708,P55,Prostate adenocarcinoma
pca_p55_ds,,,,,,,PCa_P55_DS,GSM1471709,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471709/suppl/GSM1471709_US22502614_252800412690_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471709,P55,Prostate adenocarcinoma
pca_x40_n,,,,,,,PCa_X40_N,GSM1471710,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471710/suppl/GSM1471710_US22502614_252800412691_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471710,X40,Prostate adenocarcinoma
pca_x40_ds,,,,,,,PCa_X40_DS,GSM1471711,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471711/suppl/GSM1471711_US22502614_252800412691_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471711,X40,Prostate adenocarcinoma
pca_b12_n,,,,,,,PCa_B12_N,GSM1471712,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471712/suppl/GSM1471712_US22502614_252800412691_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471712,B12,Prostate adenocarcinoma
pca_b12_ds,,,,,,,PCa_B12_DS,GSM1471713,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471713/suppl/GSM1471713_US22502614_252800412691_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471713,B12,Prostate adenocarcinoma
pca_b17_n,,,,,,,PCa_B17_N,GSM1471714,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471714/suppl/GSM1471714_US22502614_252800412691_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471714,B17,Prostate adenocarcinoma
pca_b17_ds,,,,,,,PCa_B17_DS,GSM1471715,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471715/suppl/GSM1471715_US22502614_252800412691_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471715,B17,Prostate adenocarcinoma
pca_aa65_n,,,,,,,PCa_AA65_N,GSM1471716,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471716/suppl/GSM1471716_US22502614_252800412714_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471716,AA65,Prostate adenocarcinoma
pca_aa65_ds,,,,,,,PCa_AA65_DS,GSM1471717,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471717/suppl/GSM1471717_US22502614_252800412714_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471717,AA65,Prostate adenocarcinoma
pca_c27_n,,,,,,,PCa_C27_N,GSM1471718,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471718/suppl/GSM1471718_US22502614_252800412714_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471718,C27,Prostate adenocarcinoma
pca_c27_ds,,,,,,,PCa_C27_DS,GSM1471719,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471719/suppl/GSM1471719_US22502614_252800412714_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471719,C27,Prostate adenocarcinoma
pca_aa69_n,,,,,,,PCa_AA69_N,GSM1471720,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471720/suppl/GSM1471720_US22502614_252800412715_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471720,AA69,Prostate adenocarcinoma
pca_aa69_ds,,,,,,,PCa_AA69_DS,GSM1471721,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471721/suppl/GSM1471721_US22502614_252800412715_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471721,AA69,Prostate adenocarcinoma
pca_bb5_n,,,,,,,PCa_BB5_N,GSM1471722,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471722/suppl/GSM1471722_US22502614_252800412715_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471722,BB5,Prostate adenocarcinoma
pca_bb5_ds,,,,,,,PCa_BB5_DS,GSM1471723,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471723/suppl/GSM1471723_US22502614_252800412715_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471723,BB5,Prostate adenocarcinoma
pca_g70_n,,,,,,,PCa_G70_N,GSM1471724,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471724/suppl/GSM1471724_US22502614_252800412715_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471724,G70,Prostate adenocarcinoma
pca_g70_ds,,,,,,,PCa_G70_DS,GSM1471725,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471725/suppl/GSM1471725_US22502614_252800412715_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471725,G70,Prostate adenocarcinoma
pca_m26_n,,,,,,,PCa_M26_N,GSM1471726,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471726/suppl/GSM1471726_US22502614_252800412715_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471726,M26,Prostate adenocarcinoma
pca_m26_ds,,,,,,,PCa_M26_DS,GSM1471727,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471727/suppl/GSM1471727_US22502614_252800412715_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471727,M26,Prostate adenocarcinoma
pca_v18_n,,,,,,,PCa_V18_N,GSM1471728,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471728/suppl/GSM1471728_US22502614_252800412716_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471728,V18,Prostate adenocarcinoma
pca_v18_ds,,,,,,,PCa_V18_DS,GSM1471729,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471729/suppl/GSM1471729_US22502614_252800412716_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471729,V18,Prostate adenocarcinoma
pca_w25_n,,,,,,,PCa_W25_N,GSM1471730,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471730/suppl/GSM1471730_US22502614_252800412716_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471730,W25,Prostate adenocarcinoma
pca_w25_ds,,,,,,,PCa_W25_DS,GSM1471731,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471731/suppl/GSM1471731_US22502614_252800412716_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471731,W25,Prostate adenocarcinoma
pca_y48_n,,,,,,,PCa_Y48_N,GSM1471732,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471732/suppl/GSM1471732_US22502614_252800412716_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471732,Y48,Prostate adenocarcinoma
pca_y48_ds,,,,,,,PCa_Y48_DS,GSM1471733,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471733/suppl/GSM1471733_US22502614_252800412716_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471733,Y48,Prostate adenocarcinoma
pca_z56_n,,,,,,,PCa_Z56_N,GSM1471734,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471734/suppl/GSM1471734_US22502614_252800412716_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471734,Z56,Prostate adenocarcinoma
pca_z56_ds,,,,,,,PCa_Z56_DS,GSM1471735,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471735/suppl/GSM1471735_US22502614_252800412716_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471735,Z56,Prostate adenocarcinoma
pca_i88_n,,,,,,,PCa_I88_N,GSM1471736,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471736/suppl/GSM1471736_US22502614_252800413712_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471736,I88,Prostate adenocarcinoma
pca_i88_ds,,,,,,,PCa_I88_DS,GSM1471737,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471737/suppl/GSM1471737_US22502614_252800413712_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471737,I88,Prostate adenocarcinoma
pca_z59_n,,,,,,,PCa_Z59_N,GSM1471738,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471738/suppl/GSM1471738_US22502614_252800413713_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471738,Z59,Prostate adenocarcinoma
pca_z59_ds,,,,,,,PCa_Z59_DS,GSM1471739,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471739/suppl/GSM1471739_US22502614_252800413713_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471739,Z59,Prostate adenocarcinoma
pca_aa79_n,,,,,,,PCa_AA79_N,GSM1471740,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471740/suppl/GSM1471740_US22502614_252800413713_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471740,AA79,Prostate adenocarcinoma
pca_aa79_ds,,,,,,,PCa_AA79_DS,GSM1471741,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471741/suppl/GSM1471741_US22502614_252800413713_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471741,AA79,Prostate adenocarcinoma
pca_aa88_n,,,,,,,PCa_AA88_N,GSM1471742,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471742/suppl/GSM1471742_US22502614_252800413713_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471742,AA88,Prostate adenocarcinoma
pca_aa88_ds,,,,,,,PCa_AA88_DS,GSM1471743,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471743/suppl/GSM1471743_US22502614_252800413713_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471743,AA88,Prostate adenocarcinoma
pca_g65_n,,,,,,,PCa_G65_N,GSM1471744,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471744/suppl/GSM1471744_US22502614_252800413714_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471744,G65,Prostate adenocarcinoma
pca_g65_ds,,,,,,,PCa_G65_DS,GSM1471745,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471745/suppl/GSM1471745_US22502614_252800413714_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471745,G65,Prostate adenocarcinoma
pca_cryo_n,,,,,,,PCa_CRYO_N,GSM1471746,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471746/suppl/GSM1471746_US22502614_252800413714_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471746,CRYO,Prostate adenocarcinoma
pca_cryo_ds,,,,,,,PCa_CRYO_DS,GSM1471747,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471747/suppl/GSM1471747_US22502614_252800413714_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471747,CRYO,Prostate adenocarcinoma
pca_bb36_n,,,,,,,PCa_BB36_N,GSM1471748,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471748/suppl/GSM1471748_US22502614_252800413714_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471748,BB36,Prostate adenocarcinoma
pca_bb36_ds,,,,,,,PCa_BB36_DS,GSM1471749,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471749/suppl/GSM1471749_US22502614_252800413714_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471749,BB36,Prostate adenocarcinoma
pca_l12_n,,,,,,,PCa_L12_N,GSM1471750,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471750/suppl/GSM1471750_US22502614_252800413729_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471750,L12,Prostate adenocarcinoma
pca_l12_ds,,,,,,,PCa_L12_DS,GSM1471751,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471751/suppl/GSM1471751_US22502614_252800413729_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471751,L12,Prostate adenocarcinoma
pca_k6_n,,,,,,,PCa_K6_N,GSM1471752,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471752/suppl/GSM1471752_US22502614_252800413729_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471752,K6,Prostate adenocarcinoma
pca_k6_ds,,,,,,,PCa_K6_DS,GSM1471753,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471753/suppl/GSM1471753_US22502614_252800413729_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471753,K6,Prostate adenocarcinoma
pca_p60_n,,,,,,,PCa_P60_N,GSM1471754,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471754/suppl/GSM1471754_US22502614_252800413729_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471754,P60,Prostate adenocarcinoma
pca_p60_ds,,,,,,,PCa_P60_DS,GSM1471755,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471755/suppl/GSM1471755_US22502614_252800413729_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471755,P60,Prostate adenocarcinoma
pca_w28_n,,,,,,,PCa_W28_N,GSM1471756,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471756/suppl/GSM1471756_US22502614_252800413729_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471756,W28,Prostate adenocarcinoma
pca_w28_ds,,,,,,,PCa_W28_DS,GSM1471757,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471757/suppl/GSM1471757_US22502614_252800413729_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471757,W28,Prostate adenocarcinoma
pca_a3_n,,,,,,,PCa_A3_N,GSM1471758,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471758/suppl/GSM1471758_US22502614_252800413730_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471758,A3,Prostate adenocarcinoma
pca_a3_ds,,,,,,,PCa_A3_DS,GSM1471759,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471759/suppl/GSM1471759_US22502614_252800413730_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471759,A3,Prostate adenocarcinoma
pca_c25_n,,,,,,,PCa_C25_N,GSM1471760,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471760/suppl/GSM1471760_US22502614_252800413730_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471760,C25,Prostate adenocarcinoma
pca_c25_ds,,,,,,,PCa_C25_DS,GSM1471761,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471761/suppl/GSM1471761_US22502614_252800413730_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471761,C25,Prostate adenocarcinoma
pca_h75_n,,,,,,,PCa_H75_N,GSM1471762,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471762/suppl/GSM1471762_US22502614_252800413730_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471762,H75,Prostate adenocarcinoma
pca_h75_ds,,,,,,,PCa_H75_DS,GSM1471763,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471763/suppl/GSM1471763_US22502614_252800413730_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471763,H75,Prostate adenocarcinoma
pca_z55_n,,,,,,,PCa_Z55_N,GSM1471764,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471764/suppl/GSM1471764_US22502614_252800413730_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471764,Z55,Prostate adenocarcinoma
pca_z55_ds,,,,,,,PCa_Z55_DS,GSM1471765,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471765/suppl/GSM1471765_US22502614_252800413730_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471765,Z55,Prostate adenocarcinoma
pca_cc3_n,,,,,,,PCa_CC3_N,GSM1471766,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471766/suppl/GSM1471766_US22502614_252800413731_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471766,CC3,Prostate adenocarcinoma
pca_cc3_ds,,,,,,,PCa_CC3_DS,GSM1471767,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471767/suppl/GSM1471767_US22502614_252800413731_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471767,CC3,Prostate adenocarcinoma
pca_cc17_n,,,,,,,PCa_CC17_N,GSM1471768,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471768/suppl/GSM1471768_US22502614_252800413731_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471768,CC17,Prostate adenocarcinoma
pca_cc17_ds,,,,,,,PCa_CC17_DS,GSM1471769,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471769/suppl/GSM1471769_US22502614_252800413731_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471769,CC17,Prostate adenocarcinoma
pca_cc41_n,,,,,,,PCa_CC41_N,GSM1471770,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471770/suppl/GSM1471770_US22502614_252800413731_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471770,CC41,Prostate adenocarcinoma
pca_cc41_ds,,,,,,,PCa_CC41_DS,GSM1471771,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471771/suppl/GSM1471771_US22502614_252800413731_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471771,CC41,Prostate adenocarcinoma
pca_q70_n,,,,,,,PCa_Q70_N,GSM1471772,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471772/suppl/GSM1471772_US22502614_252800413770_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471772,Q70,Prostate adenocarcinoma
pca_q70_ds,,,,,,,PCa_Q70_DS,GSM1471773,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471773/suppl/GSM1471773_US22502614_252800413770_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471773,Q70,Prostate adenocarcinoma
pca_p57_n,,,,,,,PCa_P57_N,GSM1471774,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471774/suppl/GSM1471774_US22502614_252800413770_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471774,P57,Prostate adenocarcinoma
pca_p57_ds,,,,,,,PCa_P57_DS,GSM1471775,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471775/suppl/GSM1471775_US22502614_252800413770_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471775,P57,Prostate adenocarcinoma
pca_cc62_n,,,,,,,PCa_CC62_N,GSM1471776,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471776/suppl/GSM1471776_US22502614_252800413781_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471776,CC62,Prostate adenocarcinoma
pca_cc62_ds,,,,,,,PCa_CC62_DS,GSM1471777,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471777/suppl/GSM1471777_US22502614_252800413781_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471777,CC62,Prostate adenocarcinoma
pca_i81_n,,,,,,,PCa_I81_N,GSM1471778,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471778/suppl/GSM1471778_US22502614_252800413781_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471778,I81,Prostate adenocarcinoma
pca_i81_ds,,,,,,,PCa_I81_DS,GSM1471779,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471779/suppl/GSM1471779_US22502614_252800413781_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471779,I81,Prostate adenocarcinoma
pca_cc75_n,,,,,,,PCa_CC75_N,GSM1471780,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471780/suppl/GSM1471780_US22502614_252800413981_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471780,CC75,Prostate adenocarcinoma
pca_cc75_ds,,,,,,,PCa_CC75_DS,GSM1471781,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471781/suppl/GSM1471781_US22502614_252800413981_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471781,CC75,Prostate adenocarcinoma
pca_cc83_n,,,,,,,PCa_CC83_N,GSM1471782,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471782/suppl/GSM1471782_US22502614_252800413981_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471782,CC83,Prostate adenocarcinoma
pca_cc83_ds,,,,,,,PCa_CC83_DS,GSM1471783,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471783/suppl/GSM1471783_US22502614_252800413981_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471783,CC83,Prostate adenocarcinoma
pca_cc87_n,,,,,,,PCa_CC87_N,GSM1471784,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471784/suppl/GSM1471784_US22502614_252800413981_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471784,CC87,Prostate adenocarcinoma
pca_cc87_ds,,,,,,,PCa_CC87_DS,GSM1471785,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471785/suppl/GSM1471785_US22502614_252800413981_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471785,CC87,Prostate adenocarcinoma
pca_cc91_n,,,,,,,PCa_CC91_N,GSM1471786,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471786/suppl/GSM1471786_US22502614_252800413981_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471786,CC91,Prostate adenocarcinoma
pca_cc91_ds,,,,,,,PCa_CC91_DS,GSM1471787,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471787/suppl/GSM1471787_US22502614_252800413981_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471787,CC91,Prostate adenocarcinoma
pca_d37_n,,,,,,,PCa_D37_N,GSM1471788,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471788/suppl/GSM1471788_US22502614_252800413982_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471788,D37,Prostate adenocarcinoma
pca_d37_ds,,,,,,,PCa_D37_DS,GSM1471789,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471789/suppl/GSM1471789_US22502614_252800413982_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471789,D37,Prostate adenocarcinoma
pca_a2_n,,,,,,,PCa_A2_N,GSM1471790,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471790/suppl/GSM1471790_US22502614_252800413982_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471790,A2,Prostate adenocarcinoma
pca_a2_ds,,,,,,,PCa_A2_DS,GSM1471791,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471791/suppl/GSM1471791_US22502614_252800413982_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471791,A2,Prostate adenocarcinoma
pca_cc35_n,,,,,,,PCa_CC35_N,GSM1471792,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471792/suppl/GSM1471792_US22502614_252800413982_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471792,CC35,Prostate adenocarcinoma
pca_cc35_ds,,,,,,,PCa_CC35_DS,GSM1471793,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471793/suppl/GSM1471793_US22502614_252800413982_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471793,CC35,Prostate adenocarcinoma
pca_cc8_n,,,,,,,PCa_CC8_N,GSM1471794,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471794/suppl/GSM1471794_US22502614_252800413982_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471794,CC8,Prostate adenocarcinoma
pca_cc8_ds,,,,,,,PCa_CC8_DS,GSM1471795,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471795/suppl/GSM1471795_US22502614_252800413982_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471795,CC8,Prostate adenocarcinoma
pca_d40_n,,,,,,,PCa_D40_N,GSM1471796,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471796/suppl/GSM1471796_US22502614_252800413983_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471796,D40,Prostate adenocarcinoma
pca_d40_ds,,,,,,,PCa_D40_DS,GSM1471797,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471797/suppl/GSM1471797_US22502614_252800413983_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471797,D40,Prostate adenocarcinoma
pca_a9_n,,,,,,,PCa_A9_N,GSM1471798,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471798/suppl/GSM1471798_US22502614_252800413983_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471798,A9,Prostate adenocarcinoma
pca_a9_ds,,,,,,,PCa_A9_DS,GSM1471799,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471799/suppl/GSM1471799_US22502614_252800413983_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471799,A9,Prostate adenocarcinoma
pca_l16_n,,,,,,,PCa_L16_N,GSM1471800,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471800/suppl/GSM1471800_US22502614_252800413983_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471800,L16,Prostate adenocarcinoma
pca_l16_ds,,,,,,,PCa_L16_DS,GSM1471801,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471801/suppl/GSM1471801_US22502614_252800413983_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471801,L16,Prostate adenocarcinoma
pca_f51_n,,,,,,,PCa_F51_N,GSM1471802,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471802/suppl/GSM1471802_US22502614_252800413983_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471802,F51,Prostate adenocarcinoma
pca_f51_ds,,,,,,,PCa_F51_DS,GSM1471803,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Cancer,Homo sapiens,9606,NA,NA,total RNA,Cy3,Prostate adenocarcinoma from Caucasian men vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471803/suppl/GSM1471803_US22502614_252800413983_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471803,F51,Prostate adenocarcinoma
normal_t229_n,,,,,,,Normal_T229_N,GSM1471804,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471804/suppl/GSM1471804_US22502614_252800414490_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471804,T229,Normal Prostate
normal_t229_ds,,,,,,,Normal_T229_DS,GSM1471805,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471805/suppl/GSM1471805_US22502614_252800414490_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471805,T229,Normal Prostate
normal_t66_n,,,,,,,Normal_T66_N,GSM1471806,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471806/suppl/GSM1471806_US22502614_252800414491_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471806,T66,Normal Prostate
normal_t66_ds,,,,,,,Normal_T66_DS,GSM1471807,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471807/suppl/GSM1471807_US22502614_252800414491_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471807,T66,Normal Prostate
normal_t190_n,,,,,,,Normal_T190_N,GSM1471808,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471808/suppl/GSM1471808_US22502614_252800414491_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471808,T190,Normal Prostate
normal_t190_ds,,,,,,,Normal_T190_DS,GSM1471809,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471809/suppl/GSM1471809_US22502614_252800414491_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471809,T190,Normal Prostate
normal_t138_n,,,,,,,Normal_T138_N,GSM1471810,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471810/suppl/GSM1471810_US22502614_252800414491_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471810,T138,Normal Prostate
normal_t138_ds,,,,,,,Normal_T138_DS,GSM1471811,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471811/suppl/GSM1471811_US22502614_252800414491_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471811,T138,Normal Prostate
normal_t63_n,,,,,,,Normal_T63_N,GSM1471812,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471812/suppl/GSM1471812_US22502614_252800414491_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471812,T63,Normal Prostate
normal_t63_ds,,,,,,,Normal_T63_DS,GSM1471813,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471813/suppl/GSM1471813_US22502614_252800414491_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471813,T63,Normal Prostate
normal_t191_n,,,,,,,Normal_T191_N,GSM1471814,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471814/suppl/GSM1471814_US22502614_252800417436_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471814,T191,Normal Prostate
normal_t191_ds,,,,,,,Normal_T191_DS,GSM1471815,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471815/suppl/GSM1471815_US22502614_252800417436_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471815,T191,Normal Prostate
normal_t188_n,,,,,,,Normal_T188_N,GSM1471816,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471816/suppl/GSM1471816_US22502614_252800417436_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471816,T188,Normal Prostate
normal_t188_ds,,,,,,,Normal_T188_DS,GSM1471817,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471817/suppl/GSM1471817_US22502614_252800417436_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471817,T188,Normal Prostate
normal_t218_n,,,,,,,Normal_T218_N,GSM1471818,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471818/suppl/GSM1471818_US22502614_252800417436_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471818,T218,Normal Prostate
normal_t218_ds,,,,,,,Normal_T218_DS,GSM1471819,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471819/suppl/GSM1471819_US22502614_252800417436_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471819,T218,Normal Prostate
normal_t114_n,,,,,,,Normal_T114_N,GSM1471820,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471820/suppl/GSM1471820_US22502614_252800417436_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471820,T114,Normal Prostate
normal_t114_ds,,,,,,,Normal_T114_DS,GSM1471821,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471821/suppl/GSM1471821_US22502614_252800417436_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471821,T114,Normal Prostate
normal_ps26mag05_n,,,,,,,Normal_PS26mag05_N,GSM1471822,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471822/suppl/GSM1471822_US22502614_252800413712_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471822,PS26mag05,Normal Prostate
normal_ps26mag05_ds,,,,,,,Normal_PS26mag05_DS,GSM1471823,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471823/suppl/GSM1471823_US22502614_252800413712_S01_GE2_107_Sep09_2_NO_SPIKEIN_1_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471823,PS26mag05,Normal Prostate
normal_mg16giu05_n,,,,,,,Normal_MG16giu05_N,GSM1471824,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471824/suppl/GSM1471824_US22502614_252800413712_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471824,MG16giu05,Normal Prostate
normal_mg16giu05_ds,,,,,,,Normal_MG16giu05_DS,GSM1471825,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471825/suppl/GSM1471825_US22502614_252800413712_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471825,MG16giu05,Normal Prostate
normal_dg08giu05_n,,,,,,,Normal_DG08giu05_N,GSM1471826,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471826/suppl/GSM1471826_US22502614_252800413770_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_1.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471826,DG08giu05,Normal Prostate
normal_dg08giu05_ds,,,,,,,Normal_DG08giu05_DS,GSM1471827,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471827/suppl/GSM1471827_US22502614_252800413770_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_2.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471827,DG08giu05,Normal Prostate
normal_gb08giu05_n,,,,,,,Normal_GB08giu05_N,GSM1471828,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471828/suppl/GSM1471828_US22502614_252800413714_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471828,GB08giu05,Normal Prostate
normal_gb08giu05_ds,,,,,,,Normal_GB08giu05_DS,GSM1471829,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471829/suppl/GSM1471829_US22502614_252800413714_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471829,GB08giu05,Normal Prostate
normal_cd15giu05_n,,,,,,,Normal_CD15giu05_N,GSM1471830,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy5,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (normal labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471830/suppl/GSM1471830_US22502614_252800413713_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_3.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471830,CD15giu05,Normal Prostate
normal_cd15giu05_ds,,,,,,,Normal_CD15giu05_DS,GSM1471831,Public on Mar 08 2017,Aug 12 2014,Mar 08 2017,RNA,2,Prostate Commercial Reference,Homo sapiens,9606,NA,NA,total RNA,Cy5,Normal Prostate,Homo sapiens,9606,NA,NA,total RNA,Cy3,Peripheral region of the prostate from Caucasian men without PCa vs Prostate Commercial Reference (dye-swap labelling),GPL14550,"Paola,,Ostano",Fondazione Edo ed Elvo Tempia,via Malta 3,Biella,13900,Italy,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1471nnn/GSM1471831/suppl/GSM1471831_US22502614_252800413713_S01_GE2_107_Sep09_2_NO_SPIKEIN_2_4.txt.gz,"GSE60329, GSE60371",42405,,log2 normalized Intensity values (test/reference),GSM1471831,CD15giu05,Normal Prostate
